Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Key Highlights
- ➤Edgewise (EWTX) granted inducement options covering 17,250 shares
- ➤Edgewise granted inducement RSUs covering 8,626 shares
- ➤Two new non-executive employees received the inducement awards
- ➤Options carry a $38.90 exercise price, matching October 30 closing price
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that on October 30, 2026, Edgewise granted inducement stock options to purchase a total of 17,250 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 8,626 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
Get started
Create a free account to read the full story.